ADA Publishes 2026 Standards of Care With Updates to Sections on Technology, Obesity, Cardiometabolic Disease Management
The 2026 annual updates to the Standards of Care in Diabetes include wider CGM use, guidance on dosing of antiobesity drugs, and glycemic management during cancer therapy.
Menopause Survey Reveals Top Disruptive Symptoms: Daily Dose
Your daily dose of the clinical news you may have missed.
Early Biologic Therapy for Hidradenitis Suppurativa Supported by Majority of Specialists, Survey Shows
A multinational survey of HS specialists in Europe found that 81% prescribe antibiotics despite expecting poor response and 79% favor earlier biologic initiation.
Multidisciplinary Lung Cancer Screening Program Achieves Screening Rates Above 70%: Daily Dose
Longitudinal Blood Biomarkers Show Promise for Monitoring Alzheimer's Disease Progression in Subjective Cognitive Decline
Blood-based monitoring could enable earlier intervention as approximately 20% of initially negative participants transitioned to positive biomarker status.
Topical Roflumilast 0.3% Demonstrates Significant Efficacy Across Psoriasis Severity Measures in Updated Meta-Analysis
Topical roflumilast 0.3% improved IGA, PASI, itch, and symptom scores in plaque psoriasis with a safety profile comparable to vehicle.
Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial
KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.
Quality Improvement Program Greatly Expands Sleep Apnea Testing After Stroke in VA Hospitals
The study supports the feasibility of structured operational strategies to narrow dangerous gaps in guideline-recommended inpatient OSA testing, authors wrote.
Why Nearly 1 in 5 Women Experiencing Menopause Have Wanted to Leave Their Jobs With Bruce Dorr, MD, URPS, IFM-CP
Symptoms of the menopausal transition can be so disruptive that women consider leaving employment and yet many report misdiagnosis and inappropriate treatment.
Women's Health Research Roundup for Primary Care: Key Studies At-a-Glance from TMS 2025
Highlights include widespread lack of structured menopause education in primary care residency programs, sleep benefits of elinzanetant, and more.
ACIP Votes to Modify Decades-Long Hepatitis B Birth Dose Recommendation
Amid controversy, ACIP voted today to end the universal hepatitis B birth dose for infants of HBsAg-negative mothers, shifting to clinician-guided individual decision-making.
Lecanemab Data Suggest Sustained Delay in Alzheimer Disease Progression With Long-Term Maintenance Therapy
CTAD 2025: Early, continued treatment with lecanemab may delay Alzheimer disease progression by up to 8.3 years; SC dosing demonstrates bioequivalence.
Smartphone Ownership in Young Adolescence Drives Physical and Emotional Health Risks
Adolescents acquiring smartphones at 12 showed increased risk for depression, obesity and sleep disturbances, according to a study of more than 10,000 youths.
Alzheimer's Drug Discovery Foundation Responds With Optimism to Disappointing Results from evoke Late Stage Trials
The phase 3 results offer key lessons for metabolic and inflammatory pathway targets, ADDF notes, highlighting biomarker findings that advance Alzheimer science.
New ACS Guideline Endorses Self-Collected HPV Tests for Cervical Cancer Screening
The updated guideline from the American Cancer Society introduces self-collection for HPV testing and new exit criteria to enhance accessibility.
FDA Clears Omnipod 5 Algorithm Updates, Adding 100 mg/dL Target Glucose Option
Insulet enhances the Omnipod® 5 system with new glucose targets and algorithms, improving insulin delivery for diabetes management.
“There’s Always Something We Can Do" for Agitation in Alzheimer Disease, Says Carolyn Clevenger, GNP
Clevenger, a professor of nursing at Emory University, shares practical strategies to manage agitation in Alzheimer disease, emphasizing that this symptom is treatable.
Weekly Dose Podcast: Cognitive Benefits of Quitting Smoking, LARC Counseling Impact, Hospice Prescribing Risks, New AD Blood Test, and Alcohol–Dementia Evidence
Discover key insights from the latest Weekly Dose Podcast, covering cognitive health, reproductive care, and Alzheimer diagnostics for primary care clinicians.
Semaglutide’s Setback in Alzheimer Disease Trials: Commentary on Outcomes of evoke and evoke+
Semaglutide did not slow AD progression in phase 3 evoke trials. UK and US experts express disappointment but laud value of outcomes to continuing research.
Elinzanetant Provides VMS-Independent Sleep Improvement in Postmenopausal Women: Daily Dose
CTAD 2025: Lecanemab Boosts CSF Aβ Protofibrils, Confirming Target Engagement and Pharmacodynamic Effect
New data reveals lecanemab's significant impact on amyloid-beta protofibrils in Alzheimer disease, showcasing its potential to slow disease progression.
Lifestyle Intervention Shows Benefits Beyond Cognition in US POINTER Trial, Highlighting Modifiable Risk Factors for Dementia
Two-year structured lifestyle "recipe" slowed cognitive aging and enhanced both cardiovascular and sleep health in older adults at risk for cognitive decline.
First Blood Test for Alzheimer Disease Diagnosis Cleared by FDA for Primary Care Use: Daily Dose
Why Caregivers Don't Talk About Alzheimer Agitation, With Geriatric NP Carolyn Clevenger, GNP
Nearly one-third of caregivers hesitate to discuss agitation in a patient with AD. Emory's Clevenger, shares why and how clinicians can proactively address this barrier.
New Menopause Therapies Reflect a “Sea Change” in Women’s Health, Says Lisa Larkin, MD
Lisa Larkin, MD, explains how new therapies like elinzanetant reflect a major shift in menopause care and rising demand for better clinician education.
Baxdrostat Granted FDA Priority Review for Hard-to-Control Hypertension, Could Be First-In-Class Therapy
The Priority Review decision is based on phase 3 results showing consistent SBP reductions across uncontrolled and treatment-resistant hypertension subgroups.
Obesity Linked to Faster Alzheimer Disease Progression in Longitudinal Blood Biomarker Analysis
Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.
Anti-Tau Antibody Etalanetug Reduces Novel Tau Biomarker in Phase Ib/II Study
New findings reveal etalanetug significantly reduces tau biomarkers in Alzheimer’s patients, paving the way for innovative blood-based assessments of tau pathology.
WHO Issues First Guidelines on GLP-1 Receptor Agonists for Obesity Treatment
The landmark global policy recognizes obesity as chronic disease requiring lifelong care, warns of inequitable access and proposes 3-pillar strategy targeting prevention, screening, treatment.
Understanding Agitation in Alzheimer's: Why Memory Care Isn't Enough – with Carolyn Clevenger, GNP
Emory's Clevenger discusses the neurotransmitter dysregulation behind agitation in AD and why memory-focused care doesn't address behavioral symptoms.
